Politicians should not forget that, whilst new drugs do save individual lives, they do not (usually) affect populations. An exception is the potential of Statins in preventing heart disease. Most cancer drugs are low volume and therefore high cost…. Sometimes it is reasonable to restrict access, such as hyperbaric oxygen for MS.
People with cancer and dementia will be denied treatment by “devastating” changes which put cost cutting before patients, charities have warned.
Campaigners predict a bleak future as health chiefs prepare to impose tight restrictions on expensive new drugs even if they are cost effective.
Britain will fall further behind the rest of Europe in giving patients life-saving treatments if there is not a rethink of plans that amount to “rationing pure and simple”, charity leaders say. They are responding to plans, revealed by The Times this month, to give NHS England the power to restrict or delay treatments that cost more than £20 million a year.
Bosses believe this will stop other services having to be cut to pay for the medicines, while putting pressure on drug companies to lower prices.
All drugs approved by the National Institute for Health and Care Excellence (Nice) will be subjected to an extra affordability test.
Mark Flannaghan warned on 16th May and backed this up with a letter in the Times 31st October 2016: Leading cancer charities call on PM to reform ‘outdated’ NICE drug appraisal process – Experts warn that without wider NICE reform, many effective cancer medicines will not be available to patients in the future.
Mr Haldenby needs to come clean on whether cancer drugs should be rationed, and if so how.